ema prac naion semaglutide very rare side effect 2025 is a - Semaglutideeye problems very rare EMA PRAC Concludes NAION is a Very Rare Side Effect of Semaglutide in 2025

NAION semaglutideReddit In 2025, a significant safety review by the European Medicines Agency (EMA) and its Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that non-arteritic anterior ischemic optic neuropathy (NAION) is a very rare side effect associated with semaglutide medications.PRAC concludes eye condition NAION is a very rare side ... This development follows extensive assessment by regulatory bodies and addresses concerns regarding potential vision impairment in individuals using these widely prescribed drugs.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is commonly prescribed for the treatment of type 2 diabetes and, more recently, for weight management.Semaglutide-related optic neuropathy | Reactions Weekly Medications such as Ozempic, Rybelsus, and Wegovy, all containing semaglutide, have been the subject of this review. The EMA's PRAC has officially recommended that the product information for semaglutide medicines be updated to reflect this finding, underscoring the agency's commitment to patient safety and transparency of information2025年6月6日—Patients taking weight-loss and diabetes drugs Wegovy and Ozempic have an increased risk of developinga rareeye condition that could lead to loss of vision..

The PRAC's conclusion, reached after a thorough review of available data, indicates that NAION is a very rare side effect of semaglutide, potentially affecting up to 1 in 10,000 users.2025年6月6日—Data from clinical trials also point toaslightly higher risk of developingthecondition in people takingsemaglutidecompared with people ... NAION is a serious eye condition that occurs when blood flow to the optic nerve is interrupted, which can lead to sudden vision loss or a rapid worsening of eyesight. While the incidence is extremely low, the potential for severe visual impairment necessitates clear communication to both healthcare professionals and patients.

Data from various clinical trials have suggested a slightly elevated risk of NAION in patients taking semaglutide compared to those on a placebo. The EMA's formal recognition of NAION as a semaglutide side effect has significant implications, including potential updates to drug labeling and patient counseling protocols. Earlier in 2025, the PRAC had initiated a review of semaglutide medicines precisely due to concerns surrounding an increased risk of developing NAION. Prior research, at that time, had not been strong enough to suggest a definitive link, but subsequent data prompted further investigationOther safety alerts - 2025-01-18 (1).

Healthcare providers are advised to remain vigilant and counsel patients on the signs and symptoms of NAION.2024年12月20日—The EMAstated that prior research had not been strong enough to suggestapotential link betweensemaglutideandNAION, but thesemostrecent ... If patients experience a sudden loss of vision or rapidly worsening eyesight during treatment with semaglutide, they should contact their doctor immediately. Early detection and intervention are crucial in managing any potential visual impairment. The inclusion of NAION in the product information serves as a vital alert, ensuring that patients and physicians are aware of this rare but serious potential complication.EU safety committee says semaglutide carries 'very rare' ...

The World Health Organization (WHO) also issued a medical product alert highlighting NAION as a potential risk associated with semaglutide medications in 2025Novo Nordisk's Wegovy Tied To Increased Risk Of Rare .... Echoing the EMA's findings, the WHO's acknowledgment further solidifies the rare nature of this side effect, but also emphasizes the importance of awareness. The regulatory updates aim to provide comprehensive safety information and support informed decision-making for individuals using semaglutide for their health conditions.

In summary, the EMA PRAC conclusion in 2025 that non-arteritic anterior ischemic optic neuropathy (NAION) is a very rare side effect of semaglutide medications, including Ozempic, Rybelsus, and Wegovy, represents a critical update in drug safety information2025年6月6日—EMA:PRACconcludes eye conditionNAIONis avery rare side effectofsemaglutidemedicines Ozempic, Rybelsus and Wegovy.. This establishes NAION as a very rare side effect of semaglutide drugs, with the EMA recommending necessary label changes. Patients and healthcare providers should be aware of this rare possibility and report any sudden changes in vision promptly. The EMA's PRAC has clearly defined NAION as a very rare side effect, underscoring the low probability but significant impact of this eye condition.